Top Clinical Trials companies in Japan by Gross Profit
Japan
# |
Name |
Gross Profit |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD 158.97 M
|
Dec. 31, 2023 | USD 19.77 | 1.11% |
|
Japan |
|
| 2 |
USD 94.36 M
|
March 31, 2024 | USD 10.78 | 1.91% |
|
Japan |
|
| 3 |
USD 31.26 M
|
Dec. 31, 2023 | USD 1.27 | -1.66% |
|
Japan |
|
| 4 |
USD 11.74 M
|
Dec. 31, 2023 | USD 2.46 | -0.69% |
|
Japan |
|
| 5 |
USD 8.54 M
|
March 31, 2024 | USD 5.61 | 0.04% |
|
Japan |
|
| 6 |
USD 7.90 M
|
March 31, 2024 | USD 2.06 | -4.87% |
|
Japan |
|
| 7 |
USD 216.90 K
|
Dec. 31, 2023 | USD 3.27 | -0.38% |
|
Japan |
|
| 8 |
USD -2.25 K
|
March 31, 2024 | USD 0.27 | -4.62% |
|
Japan |
|
| 9 |
USD -98.67 K
|
Jan. 31, 2024 | USD 4.78 | -2.00% |
|
Japan |
|
| 10 |
USD -295.81 K
|
July 31, 2024 | USD 1.94 | -0.83% |
|
Japan |
|
| 11 |
USD -1.17 M
|
March 31, 2024 | USD 0.15 | 4.16% |
|
Japan |
|
| 12 |
USD -6.13 M
|
June 30, 2024 | USD 5.71 | -0.07% |
|
Japan |
Frequently Asked Questions
-
Which Clinical Trials company in Japan has the highest Gross Profit ?
The Clinical Trials company in Japan with the highest Gross Profit is GNI Group Ltd. (Tokyo Stock Exchange: 2160.T) at USD 158.97 M.
-
Which Clinical Trials company in Japan has the lowest Gross Profit ?
The Clinical Trials company in Japan with the lowest Gross Profit is CanBas Co., Ltd. (Tokyo Stock Exchange: 4575.T) at USD -6.13 M.
-
What are the top 10 Clinical Trials companies in Japan by Gross Profit ?
The top 10 Clinical Trials companies in Japan by Gross Profit are GNI Group Ltd., Shin Nippon Biomedical Laboratories, Ltd., SymBio Pharmaceuticals Limited, RaQualia Pharma Inc., Cytori Cell Research Institute, Inc., PhoenixBio Co., Ltd., Oncolys BioPharma Inc., BrightPath Biotherapeutics Co., Ltd., SanBio Company Limited and StemRIM.
-
What are the bottom 10 Clinical Trials companies in Japan by Gross Profit ?
The bottom 10 Clinical Trials companies in Japan by Gross Profit are CanBas Co., Ltd., OncoTherapy Science, Inc., StemRIM, SanBio Company Limited, BrightPath Biotherapeutics Co., Ltd., Oncolys BioPharma Inc., PhoenixBio Co., Ltd., Cytori Cell Research Institute, Inc., RaQualia Pharma Inc. and SymBio Pharmaceuticals Limited.